ZTS 40.23 Zoetis Inc. Class A Common Stoc $ZTS Hit
Post# of 46497
Posted On: 11/09/2014 2:44:29 PM
ZTS 40.23 Zoetis Inc. Class A Common Stoc $ZTS Hit a 52 week high of 40.30 Currently at 40.23 +0.52 +1.31% With a day low of 39.62 and a total volume of 6,818,900.
ZTS Zoetis Inc. Class A Common Stoc Recent Headline News
These Statistics Demonstrate the Staggering and Undeniable Power of Pets
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 08, 1:41PM CST
Source: Flickr user Brad Holt. Pet ownership may not be for everyone, but it's becoming more prominent than you might have first thought. According to the American Pet Products Association, or APPA, pet ownership by household in the U.S. has...
ZTS: 40.23 (+0.52), PETS: 13.28 (+0.16), WOOF: 45.85 (-0.87), PETM: 72.54 (+0.90)
Study Results, Financial Results, Regulatory Updates, and Upcoming Conference - Research Reports on Medtronic, Zoetis, Biogen, Tenet Health and Aetna
PR Newswire - Fri Nov 07, 7:55AM CST
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Zoetis Inc. (NYSE: ZTS), Biogen Idec Inc. (NASDAQ: BIIB), Tenet Healthcare Corp. (NYSE: THC) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7776-100free.
ZTS: 40.23 (+0.52), BIIB: 320.75 (-2.72), MDT: 68.10 (-0.64), THC: 47.85 (-3.33), AET: 82.29 (-2.41)
Zoetis to Participate in Piper Jaffray 26th Annual Healthcare Conference
Business Wire - Wed Nov 05, 7:30AM CST
Zoetis Inc.(NYSE:ZTS) will participate in the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, Dec. 2, in New York, N.Y. Paul Herendeen, Executive Vice President and Chief Financial Officer, and Dr. Catherine Knupp, Executive Vice President and President, Research and Development, will represent the company and respond to questions from analysts. They are scheduled to present at 8:30 a.m. EST.
ZTS: 40.23 (+0.52)
Zoetis (ZTS) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Nov 04, 6:36PM CST
The following Zoetis (ZTS) conference call took place on November 4, 2014, 08:30 AM ET. This is a transcript of that earnings call:
ZTS: 40.23 (+0.52)
Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 40.23 (+0.52), ENDP: 68.96 (-1.23), VRX: 126.11 (-2.66), PFE: 29.92 (-0.12)
Zoetis beats 3Q profit forecasts
AP - Tue Nov 04, 8:33AM CST
FLORHAM PARK, N.J. (AP) — FLORHAM PARK, N.J. (AP) — Zoetis Inc. (ZTS) on Tuesday reported third-quarter profit of $166 million.
ZTS: 40.23 (+0.52)
Zoetis Reports Third Quarter 2014 Results
Business Wire - Tue Nov 04, 6:03AM CST
--Third Quarter 2014 Reported Net Income of $166 Million, or Diluted EPS of $0.33, Increased 27%, Compared to Third Quarter 2013
ZTS: 40.23 (+0.52)
Zoetis (ZTS) Stock Gains Ahead of Third-Quarter Earnings Report
at The Street - Mon Nov 03, 2:52PM CST
Shares of Zoetis (ZTS) are gaining Monday ahead of the drug manufacturer's third-quarter earnings report before the market's open on Tuesday.
ZTS: 40.23 (+0.52)
Will Zoetis (ZTS) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 4:10PM CDT
Zoetis Inc. (ZTS) is scheduled to report third-quarter 2014 results before the opening bell on Nov 4.
ZTS: 40.23 (+0.52), ACT: 245.91 (-4.47), PFE: 29.92 (-0.12), HSP: 56.32 (-0.32)
Third Point's Daniel Loeb Tells Amgen it's Time to Break up
at The Street - Wed Oct 22, 10:36AM CDT
Amgen plans to expound on plans for the company at its Oct. 28 investor meeting.
ZTS: 40.23 (+0.52), ABT: 43.37 (-0.32), PFE: 29.92 (-0.12), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21)
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt
PR Newswire - Mon Oct 20, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Avanir Pharmaceuticals Inc. (NASDAQ: AVNR), and Mallinckrodt PLC (NYSE: MNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 17, 2014, the NASDAQ Composite ended at 4,258.44, up 0.97%, the Dow Jones Industrial Average advanced 1.63%, to finish the day at 16,380.41, and the S&P 500 closed at 1,886.76, up 1.29%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index also advancing 0.29% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MNK: 91.06 (-3.49), ZTS: 40.23 (+0.52), AGN: 196.00 (-1.40), AVNR: 13.02 (-0.19), ACT: 245.91 (-4.47)
Approval of Settlement, Philanthropic Activities, Partnership, Market Activity, and Dividend - Research Reports on Duke Energy, Lowe's, Viacom, Trinity and Zoetis
PR Newswire - Wed Oct 08, 8:20AM CDT
Today, Analysts Review released its research reports regarding Duke Energy Corp. (NYSE: DUK), Lowe's Companies, Inc. (NYSE: LOW), Viacom, Inc. (NASDAQ: VIAB), Trinity Industries Inc. (NYSE: TRN) and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7017-100free.
ZTS: 40.23 (+0.52), DUK: 82.08 (+0.91), TRN: 35.70 (+0.65), LOW: 57.69 (+0.12), VIAB: 70.63 (-0.16)
Zoetis' board announces dividend of USD0.072 per share for Q4 2014
M2 - Fri Oct 03, 4:23AM CDT
The board of directors of Zoetis (NYSE:ZTS), an animal health company, on Friday declared a fourth quarter dividend of USD0.072 per share of the company's common stock.
ZTS: 40.23 (+0.52)
Zoetis Declares Fourth Quarter 2014 Dividend
Business Wire - Thu Oct 02, 4:10PM CDT
The Board of Directors of Zoetis Inc.(NYSE:ZTS) declared a fourth quarter dividend payable to holders of the company's common stock of $0.072 per share. The dividend is to be paid on Tuesday, Dec. 2, 2014, to holders of record on Wednesday, Nov. 5, 2014.
ZTS: 40.23 (+0.52)
Zoetis to Host Webcast and Conference Call on Third Quarter 2014 Financial Results
Business Wire - Tue Sep 30, 7:31AM CDT
Zoetis Inc.(NYSE: ZTS) will host a webcast and conference call at 8:30 a.m. (EST) on Tuesday, November 4, 2014. Chief Executive Officer Juan Ramon Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review third quarter 2014 financial results and respond to questions from financial analysts during the call.
ZTS: 40.23 (+0.52)
Focusing Solely On Animal Health Sets Zoetis Apart
at Investor's Business Daily - Fri Sep 26, 1:37PM CDT
In April 2013, experts diagnosed a virus spreading quickly among America's pigs. It has since killed more than 7 million piglets in 30 states. By early summer of 2013, the leadership team at animal-health company Zoetis (ZTS) decided to develop a...
ZTS: 40.23 (+0.52), PFE: 29.92 (-0.12)
Acquisitions, Distributions, Partnerships, and Recognitions - Research Reports on Dr Pepper Snapple, AmericanTower, Allergan, Zoetis and Aetna
PR Newswire - Thu Sep 25, 7:30AM CDT
Today, Analysts Review released its research reports regarding Dr Pepper Snapple Group, Inc. (NYSE: DPS), American Tower Corporation (NYSE: AMT), Allergan Inc. (NYSE: AGN), Zoetis Inc. (NYSE: ZTS) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6743-100free.
ZTS: 40.23 (+0.52), AGN: 196.00 (-1.40), DPS: 69.95 (+0.01), AMT: 99.47 (-0.08), AET: 82.29 (-2.41)
Zoetis Ranked Among Top Ten Companies for Working Mothers
Business Wire - Tue Sep 16, 7:30AM CDT
Zoetis Inc.(NYSE:ZTS) today announced that it has been named among the top 10 on Working Mother magazine's "100 Best Companies for Working Mothers" list. The publication selects the top 100 companies in the U.S. that have demonstrated their commitment to progressive workplace programs such as child care, flexibility, advancement and paid family leave.
ZTS: 40.23 (+0.52)
Animal Healthcare Market - Global Industry Analysis 2014 - 2019: Segment, Animal type and Regional Analysis
M2 - Tue Sep 16, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/knrxpc/animal_healthcare) has announced the addition of the "Animal Healthcare Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019 Market" report to their offering. The global animal healthcare market is growing due to the increasing animal population of both types: companion and production. Companion animals are those which people tame or adopt for companionship, house/office guards and production animals are raised for meat and milk-related products. The new diseases in animals and their transfer to humans via their product consumption and companionship are also propelling the animal healthcare market globally. However, some challenges have emerged in the form of regulations against the excess use of antibiotics in production animals, and legislations and protest of animal activists and institutions against animal research. The animal healthcare market is very competitive with the top ten players accounting for about 75% of the market and every company focusing on research and development to produce better pharmaceutical and vaccine products for the existing diseases. The animal healthcare market is categorized under three broad segments, namely feed additives, pharmaceuticals and vaccines. Feed additives can be categorized as nutritional feed additives and medicinal feed additives. Nutritional feed additives comprise amino acids, minerals and vitamins and are used for production animals for their optimal growth. Medicinal feed additives comprise hormones, enzymes, immune-modulators, probiotics and prebiotics and feed acidifiers which target specific diseases in production and companion animals. Pharmaceutical products mainly include endoparasiticides, ectoparasiticides, endectocides, antibiotics, anti-inflammatories and medicines for reproductive problems. Vaccines make animals disease-immune for a particular disease. In biological terms, vaccination against a particular pathogen aims to mimic the development of naturally acquired immunity by inoculation of non-pathogenic but immunogenic components of that pathogen.omponents of that pathogen. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Animal Healthcare Market - Industry Overview Chapter 4 Global Animal Healthcare Market: By Product Segment Chapter 5 Global Animal Healthcare Market: By Animal Type Chapter 6 Global Animal Healthcare Market: By Region Chapter 7 Competitive Landscape Chapter 8 Company Profiles - Bayer AG - Boehringer Ingelheim GmbH - Ceva Sant? Animale - Elanco Products Company - MERIAL Limited - Merck & Co., Inc. - Novartis Animal Health Inc. - Virbac SA - V?toquinol SA - Zoetis Inc. For more information visit http://www.researchandmarkets.com/research/kn...healthcare
ZTS: 40.23 (+0.52), MRK: 59.34 (+0.08), NVS: 91.76 (-0.27)
Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte
PR Newswire - Tue Sep 09, 7:55AM CDT
On Monday, September 08, 2014, the NASDAQ Composite ended at 4,592.29, up 0.20%, the Dow Jones Industrial Average finished the day 0.15% lower at 17,111.42, and the S&P 500 closed at 2,001.54, down 0.31%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index ended the day at 741.59, up 0.05%, with the index gaining 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Horizon Pharma Inc. (NASDAQ: HZNP), Hospira Inc. (NYSE: HSP), and Endocyte Inc. (NASDAQ: ECYT). Free research on these five companies can be accessed at:
ZTS: 40.23 (+0.52), ECYT: 6.03 (-0.46), ACT: 245.91 (-4.47), HZNP: 12.99 (-0.27), HSP: 56.32 (-0.32)
ZTS Zoetis Inc. Class A Common Stoc Recent Headline News
These Statistics Demonstrate the Staggering and Undeniable Power of Pets
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 08, 1:41PM CST
Source: Flickr user Brad Holt. Pet ownership may not be for everyone, but it's becoming more prominent than you might have first thought. According to the American Pet Products Association, or APPA, pet ownership by household in the U.S. has...
ZTS: 40.23 (+0.52), PETS: 13.28 (+0.16), WOOF: 45.85 (-0.87), PETM: 72.54 (+0.90)
Study Results, Financial Results, Regulatory Updates, and Upcoming Conference - Research Reports on Medtronic, Zoetis, Biogen, Tenet Health and Aetna
PR Newswire - Fri Nov 07, 7:55AM CST
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Zoetis Inc. (NYSE: ZTS), Biogen Idec Inc. (NASDAQ: BIIB), Tenet Healthcare Corp. (NYSE: THC) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7776-100free.
ZTS: 40.23 (+0.52), BIIB: 320.75 (-2.72), MDT: 68.10 (-0.64), THC: 47.85 (-3.33), AET: 82.29 (-2.41)
Zoetis to Participate in Piper Jaffray 26th Annual Healthcare Conference
Business Wire - Wed Nov 05, 7:30AM CST
Zoetis Inc.(NYSE:ZTS) will participate in the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, Dec. 2, in New York, N.Y. Paul Herendeen, Executive Vice President and Chief Financial Officer, and Dr. Catherine Knupp, Executive Vice President and President, Research and Development, will represent the company and respond to questions from analysts. They are scheduled to present at 8:30 a.m. EST.
ZTS: 40.23 (+0.52)
Zoetis (ZTS) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Nov 04, 6:36PM CST
The following Zoetis (ZTS) conference call took place on November 4, 2014, 08:30 AM ET. This is a transcript of that earnings call:
ZTS: 40.23 (+0.52)
Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 40.23 (+0.52), ENDP: 68.96 (-1.23), VRX: 126.11 (-2.66), PFE: 29.92 (-0.12)
Zoetis beats 3Q profit forecasts
AP - Tue Nov 04, 8:33AM CST
FLORHAM PARK, N.J. (AP) — FLORHAM PARK, N.J. (AP) — Zoetis Inc. (ZTS) on Tuesday reported third-quarter profit of $166 million.
ZTS: 40.23 (+0.52)
Zoetis Reports Third Quarter 2014 Results
Business Wire - Tue Nov 04, 6:03AM CST
--Third Quarter 2014 Reported Net Income of $166 Million, or Diluted EPS of $0.33, Increased 27%, Compared to Third Quarter 2013
ZTS: 40.23 (+0.52)
Zoetis (ZTS) Stock Gains Ahead of Third-Quarter Earnings Report
at The Street - Mon Nov 03, 2:52PM CST
Shares of Zoetis (ZTS) are gaining Monday ahead of the drug manufacturer's third-quarter earnings report before the market's open on Tuesday.
ZTS: 40.23 (+0.52)
Will Zoetis (ZTS) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 4:10PM CDT
Zoetis Inc. (ZTS) is scheduled to report third-quarter 2014 results before the opening bell on Nov 4.
ZTS: 40.23 (+0.52), ACT: 245.91 (-4.47), PFE: 29.92 (-0.12), HSP: 56.32 (-0.32)
Third Point's Daniel Loeb Tells Amgen it's Time to Break up
at The Street - Wed Oct 22, 10:36AM CDT
Amgen plans to expound on plans for the company at its Oct. 28 investor meeting.
ZTS: 40.23 (+0.52), ABT: 43.37 (-0.32), PFE: 29.92 (-0.12), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21)
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt
PR Newswire - Mon Oct 20, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Avanir Pharmaceuticals Inc. (NASDAQ: AVNR), and Mallinckrodt PLC (NYSE: MNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 17, 2014, the NASDAQ Composite ended at 4,258.44, up 0.97%, the Dow Jones Industrial Average advanced 1.63%, to finish the day at 16,380.41, and the S&P 500 closed at 1,886.76, up 1.29%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index also advancing 0.29% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MNK: 91.06 (-3.49), ZTS: 40.23 (+0.52), AGN: 196.00 (-1.40), AVNR: 13.02 (-0.19), ACT: 245.91 (-4.47)
Approval of Settlement, Philanthropic Activities, Partnership, Market Activity, and Dividend - Research Reports on Duke Energy, Lowe's, Viacom, Trinity and Zoetis
PR Newswire - Wed Oct 08, 8:20AM CDT
Today, Analysts Review released its research reports regarding Duke Energy Corp. (NYSE: DUK), Lowe's Companies, Inc. (NYSE: LOW), Viacom, Inc. (NASDAQ: VIAB), Trinity Industries Inc. (NYSE: TRN) and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7017-100free.
ZTS: 40.23 (+0.52), DUK: 82.08 (+0.91), TRN: 35.70 (+0.65), LOW: 57.69 (+0.12), VIAB: 70.63 (-0.16)
Zoetis' board announces dividend of USD0.072 per share for Q4 2014
M2 - Fri Oct 03, 4:23AM CDT
The board of directors of Zoetis (NYSE:ZTS), an animal health company, on Friday declared a fourth quarter dividend of USD0.072 per share of the company's common stock.
ZTS: 40.23 (+0.52)
Zoetis Declares Fourth Quarter 2014 Dividend
Business Wire - Thu Oct 02, 4:10PM CDT
The Board of Directors of Zoetis Inc.(NYSE:ZTS) declared a fourth quarter dividend payable to holders of the company's common stock of $0.072 per share. The dividend is to be paid on Tuesday, Dec. 2, 2014, to holders of record on Wednesday, Nov. 5, 2014.
ZTS: 40.23 (+0.52)
Zoetis to Host Webcast and Conference Call on Third Quarter 2014 Financial Results
Business Wire - Tue Sep 30, 7:31AM CDT
Zoetis Inc.(NYSE: ZTS) will host a webcast and conference call at 8:30 a.m. (EST) on Tuesday, November 4, 2014. Chief Executive Officer Juan Ramon Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review third quarter 2014 financial results and respond to questions from financial analysts during the call.
ZTS: 40.23 (+0.52)
Focusing Solely On Animal Health Sets Zoetis Apart
at Investor's Business Daily - Fri Sep 26, 1:37PM CDT
In April 2013, experts diagnosed a virus spreading quickly among America's pigs. It has since killed more than 7 million piglets in 30 states. By early summer of 2013, the leadership team at animal-health company Zoetis (ZTS) decided to develop a...
ZTS: 40.23 (+0.52), PFE: 29.92 (-0.12)
Acquisitions, Distributions, Partnerships, and Recognitions - Research Reports on Dr Pepper Snapple, AmericanTower, Allergan, Zoetis and Aetna
PR Newswire - Thu Sep 25, 7:30AM CDT
Today, Analysts Review released its research reports regarding Dr Pepper Snapple Group, Inc. (NYSE: DPS), American Tower Corporation (NYSE: AMT), Allergan Inc. (NYSE: AGN), Zoetis Inc. (NYSE: ZTS) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6743-100free.
ZTS: 40.23 (+0.52), AGN: 196.00 (-1.40), DPS: 69.95 (+0.01), AMT: 99.47 (-0.08), AET: 82.29 (-2.41)
Zoetis Ranked Among Top Ten Companies for Working Mothers
Business Wire - Tue Sep 16, 7:30AM CDT
Zoetis Inc.(NYSE:ZTS) today announced that it has been named among the top 10 on Working Mother magazine's "100 Best Companies for Working Mothers" list. The publication selects the top 100 companies in the U.S. that have demonstrated their commitment to progressive workplace programs such as child care, flexibility, advancement and paid family leave.
ZTS: 40.23 (+0.52)
Animal Healthcare Market - Global Industry Analysis 2014 - 2019: Segment, Animal type and Regional Analysis
M2 - Tue Sep 16, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/knrxpc/animal_healthcare) has announced the addition of the "Animal Healthcare Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019 Market" report to their offering. The global animal healthcare market is growing due to the increasing animal population of both types: companion and production. Companion animals are those which people tame or adopt for companionship, house/office guards and production animals are raised for meat and milk-related products. The new diseases in animals and their transfer to humans via their product consumption and companionship are also propelling the animal healthcare market globally. However, some challenges have emerged in the form of regulations against the excess use of antibiotics in production animals, and legislations and protest of animal activists and institutions against animal research. The animal healthcare market is very competitive with the top ten players accounting for about 75% of the market and every company focusing on research and development to produce better pharmaceutical and vaccine products for the existing diseases. The animal healthcare market is categorized under three broad segments, namely feed additives, pharmaceuticals and vaccines. Feed additives can be categorized as nutritional feed additives and medicinal feed additives. Nutritional feed additives comprise amino acids, minerals and vitamins and are used for production animals for their optimal growth. Medicinal feed additives comprise hormones, enzymes, immune-modulators, probiotics and prebiotics and feed acidifiers which target specific diseases in production and companion animals. Pharmaceutical products mainly include endoparasiticides, ectoparasiticides, endectocides, antibiotics, anti-inflammatories and medicines for reproductive problems. Vaccines make animals disease-immune for a particular disease. In biological terms, vaccination against a particular pathogen aims to mimic the development of naturally acquired immunity by inoculation of non-pathogenic but immunogenic components of that pathogen.omponents of that pathogen. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Animal Healthcare Market - Industry Overview Chapter 4 Global Animal Healthcare Market: By Product Segment Chapter 5 Global Animal Healthcare Market: By Animal Type Chapter 6 Global Animal Healthcare Market: By Region Chapter 7 Competitive Landscape Chapter 8 Company Profiles - Bayer AG - Boehringer Ingelheim GmbH - Ceva Sant? Animale - Elanco Products Company - MERIAL Limited - Merck & Co., Inc. - Novartis Animal Health Inc. - Virbac SA - V?toquinol SA - Zoetis Inc. For more information visit http://www.researchandmarkets.com/research/kn...healthcare
ZTS: 40.23 (+0.52), MRK: 59.34 (+0.08), NVS: 91.76 (-0.27)
Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte
PR Newswire - Tue Sep 09, 7:55AM CDT
On Monday, September 08, 2014, the NASDAQ Composite ended at 4,592.29, up 0.20%, the Dow Jones Industrial Average finished the day 0.15% lower at 17,111.42, and the S&P 500 closed at 2,001.54, down 0.31%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index ended the day at 741.59, up 0.05%, with the index gaining 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Horizon Pharma Inc. (NASDAQ: HZNP), Hospira Inc. (NYSE: HSP), and Endocyte Inc. (NASDAQ: ECYT). Free research on these five companies can be accessed at:
ZTS: 40.23 (+0.52), ECYT: 6.03 (-0.46), ACT: 245.91 (-4.47), HZNP: 12.99 (-0.27), HSP: 56.32 (-0.32)
(0)
(0)Scroll down for more posts ▼